Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

NEW & NOTEWORTHY These studies for the first time present comprehensive data on the relative characterization of vasoactive intestinal peptide (VIP) receptors in the intestinal mucosa. Vasoactive intestinal peptide receptor 1 (VPAC1) was identified as the predominant receptor with higher levels in the colon compared with the small intestine and was mainly localized to the apical membrane. In addition, the findings in the human tissues were consistent with VPAC1 expression in the mouse intestine and open possibilities to target colonic tissues with VIP for treating diseases such as inflammatory bowel disease.

https://journals.physiology.org/doi/full/10.1152/ajpgi.00081.2017

The global inflammatory bowel disease treatment market size was valued at USD 15.9 billion in 2018 and is expected to register a CAGR of 4.4% from 2018 to 2026. Presence of strong pipeline products for the treatment of inflammatory bowel disease (IBD) is anticipated to drive the market over the forecast period.

https://www.grandviewresearch.com/industry-analysis/inflammatory-bowel-disease-ibd-treatment-market